Navigation Links
TechniScan Signs Agreement With Texas-Based Company to Co-Develop A New Version of Its Breast Imaging Device
Date:1/18/2011

SALT LAKE CITY, Jan. 18, 2011 /PRNewswire/ -- TechniScan (OTC Bulletin Board: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, announced today that it has signed a Product Development Agreement with Austin, Texas based Womens3D, Inc. worth a minimum of $1.5 million.

TechniScan and Womens3D will co-develop technology specifically for Womens3D's proposed target market that is directed toward women's health practices.  

Under the terms of the agreement, Womens3D acquired a prototype of the TechniScan WBU system for $250,000 and contemplates contributing at least $1.25 million more to support development of a specialized whole breast ultrasound imaging system based on the TechniScan Warm Bath Ultrasound (WBU) product now in clinical testing. In addition, TechniScan will supply technical support of the product and customization of the imaging network applications that will be used in part to store and transmit the image files.

"As a part of the Development Agreement, we purchased a prototype WBU system for evaluation, and we are now very excited to be working with TechniScan and welcome their expertise as we address the needs of the developing markets in women's health," said Scott Sanders, chief executive officer of Womens3D.  

Womens3D's Chief Science Officer, Mark Lenox, Ph.D., formerly part of the engineering team that performed the research and early development and commercialization of Positron Emission Tomography (PET) in nuclear medical imaging, conducted the technical evaluation of TechniScan's WBU system.  

TechniScan's Warm Bath Ultrasound (WBU) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table while proprietary ultrasound technology in a warm water tank images the breast anatomy.  This new method of imaging produces diagnostic information that is not available with traditional hand-held ultrasound or whole breast ultrasound systems presently on the market.

"TechniScan is excited to be working with Womens3D on this development program, which potentially will open new markets for our equipment and add a valuable partner to our development efforts. Over the next one to two years we expect to complete the development of an ultrasound system for Womens3D based on our technology," said Dave Robinson, chief executive officer of TechniScan.

A more complete and detailed description of the Product Development Agreement is set forth in TechniScan's current report on Form 8-K filed today with the Securities and Exchange Commission.

About TechniScan

TechniScan, Inc., is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's WBU™ imaging device is limited by U.S. law to investigational use, unless and until cleared by the FDA.  For more information, please visit www.tsni.com.

About Womens3D

Womens3D, Inc., is an early stage medical device company engaged in the development and commercialization of imaging solutions designed to provide women's health practices with powerful new tools that can deliver rapid and clinically effective diagnostic breast imaging at the point of care.  For more information please visit www.Womens3D.com.

Forward-Looking Statements Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of TechniScan, Inc. (the "company") to be materially different from those expressed or implied by such forward-looking statements.  The company's future operating results are dependent upon many factors, including risk factors discussed in the company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the company's Annual Report on Form 10-K filed on March 22, 2010. The company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For More Information:
Dave Robinson
TechniScan Medical Systems
(801) 994-2965
drobinson@tsni.com




'/>"/>
SOURCE TechniScan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
3. TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
4. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
5. TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
6. TechniScan, Inc. Announces Restructuring of Convertible Debt
7. TechniScan Secures $10 Million Equity Financing Facility
8. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
9. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):